Roche's Q1 pipeline cleanup claims PhII myelofibrosis drug, early-stage MAGE-A4 work
More than three years after Roche put down $390 million in cash to buy the biotech Promedior, the anti-fibrotic drug at the center of the deal is gone from the pipeline.
Roche’s first-quarter presentation shows that a Phase II trial for zinpentraxin alfa (PRM-151) in myelofibrosis has been cut — which a spokesperson said was “due to portfolio re-prioritisation.” During its last quarterly update, Roche had already said that it was shutting down a Phase III study in idiopathic pulmonary fibrosis following a futility analysis, but kept the myelofibrosis study and anticipated a 2025 filing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.